Waltham, MA, United States
Waltham, MA, United States

Time filter

Source Type

Patent
ImmunoGen | Date: 2016-07-27

The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepine compounds of formula (I)-(VII). The invention also provides conjugates of the benzodiazepine compounds linked to a cell-binding agent. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.


Patent
ImmunoGen | Date: 2016-07-21

The invention relates to novel methods for preparing indolinobenzodiazepine dimer compounds and their synthetic precursors.


Patent
ImmunoGen | Date: 2016-07-21

The invention relates to novel methods for preparing indolinobenzodiazepine dimer compounds and their synthetic precursors.


The invention provides a one-step process for preparing a cell-binding agent cytotoxic agent conjugate comprising contacting a cell-binding agent with a cytotoxic agent to form a first mixture comprising the cell-binding agent and the cytotoxic agent and contacting the first mixture comprising the cell-binding agent and the cytotoxic agent with a bifunctional crosslinking reagent, which provides a linker, in a solution having a pH of about 4 to about 9 to provide a second mixture comprising the cell-binding agent cytotoxic agent conjugate, wherein the cell-binding agent is chemically coupled through the linker to the cytotoxic agent, free cytotoxic agent, and reaction by-products. The second mixture is then optionally subjected to purification to provide a purified cell-binding agent cytotoxic agent conjugate.


Patent
Biotest Ag and ImmunoGen | Date: 2016-06-18

Disclosed are immunoconjugates having in particular specificity for CD138 expressed on target cells and which display homogenous targeting. The immunoconjugates may be sterially hindered and/or contain a cleavable linker.


Patent
ImmunoGen | Date: 2016-07-21

The invention relates to novel methods for preparing indolinobenzodiazepine dimer compounds and their synthetic precursors.


Patent
ImmunoGen and Genentech | Date: 2016-06-01

The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.


Therapeutic combinations of immunoconjugates that bind to FOLR1 (e.g., IMGN853) with anti-VEGF agents (e.g., bevacizumab), a platinum-based agent, and/or doxorubicin are provided. Methods of administering the combinations to treat cancers, e.g., ovarian cancers, with greater clinical efficacy and/or decreased toxicity are also provided.


Patent
ImmunoGen | Date: 2016-09-19

Disclosed is a method of preparing an amino acid ester of maytansinol by reacting maytansinol with an N-carboxyanhydride of an amino acid (NCA) in the presence of a drying agent. Also disclosed is an improved method of preparing an amino acid ester of maytansinol in which a nucleophile is added to the reaction mixture after completion of the reaction between maytansinol and an N-carboxyanhydride of an amino acid.


The invention features methods for characterizing and treating acute myeloid leukemia (AML) (e.g., newly diagnosed, relapsed, and refractory AML) in a subject using immunoconjugates of the invention. In one aspect, the invention generally features a method of treating acute myeloid leukemia in a subject (e.g., a human), the method involving administering an effective amount of an immunoconjugate to a pre-selected subject, where the immunoconjugate contains a humanized or chimeric antibody or fragment conjugated to a cytotoxic benzodiazepine dimer compound via a cleavable disulfide linker.

Loading ImmunoGen collaborators
Loading ImmunoGen collaborators